BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
화요일, 9월 15

Recursion Pharmaceuticals Inc

RXRXNASDAQ
Trade with Public
Trade with Public
$3.25
-0.17-4.84%
가까이에: Sep 15, 5:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Recursion Pharmaceuticals Financials

Recursion Pharmaceuticals (RXRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 39.02 percent increase over losses of $(0.41) per
Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Recursion Pharmaceuticals Q1 EPS $(0.22) Beats $(0.27) Estimate, Sales $6.472M Miss $15.777M Estimate

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.27) by 18.52 percent. This is a 56 percent increase over losses of $(0.50) per share
Benzinga Newsdesk

PRO
Recursion's 2025 Cash Balance Was $753.9M With Expected Cash Runway Extending Into Early 2028

Benzinga Newsdesk

Recursion Pharmaceuticals Q4 Earnings Report: What Investors Need to Know

Benzinga Insights

PRO
Recursion Pharmaceuticals Q4 2025 EPS $(0.21) Beats $(0.27) Estimate, Sales $35.537M Beat $24.586M Estimate

Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved